Results 21 to 30 of about 2,749 (135)

TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma

BMC Cancer, 2023
Background At present, there are a variety of antiviral drugs for HBV in clinical practice, but there is no standard scheme for transcatheter arterial chemoembolization(TACE) combined with antiviral drugs. The aim of this study was to investigate whether
Haohao Lu, Chuansheng Zheng, Bin Xiong, Xiangwen Xia   +3 more
doaj   +1 more source

Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067.

PLoS ONE, 2018
Tenofovir (TFV), a nucleotide reverse transcriptase inhibitor, requires two phosphorylation steps to form a competitive inhibitor of HIV reverse transcriptase.
Dominique B Figueroa, Joseph Tillotson, Maoji Li, Estelle Piwowar-Manning, Craig W Hendrix, Timothy H Holtz, Kevin Bokoch, Linda-Gail Bekker, Frits van Griensven, Sharon Mannheimer, James P Hughes, Robert M Grant, Namandjé N Bumpus   +12 more
doaj   +1 more source

The Role of Drug Transporters in the Kidney: Lessons from Tenofovir

Frontiers in Pharmacology, 2014
Tenofovir disoproxil fumarate, the prodrug of nucleotide reverse transcriptase inhibitor tenofovir, shows high efficacy and relatively low toxicity in HIV patients.
Darren Michael Moss, Megan eNeary, Andrew eOwen   +2 more
doaj   +1 more source

Guides concerning tenofovir exposure via breastfeeding: A comparison of drug dosages by developmental stage

International Journal of Infectious Diseases, 2019
Tenofovir disoproxil fumarate (TDF) is a prodrug of tenofovir, and after being administered orally, it converts to tenofovir in the blood. With the increasing use of TDF in women for treatment and prevention of mother-to-child transmission (MTCT) of both
Xiaotong Hu, Liming Wang, Fujie Xu
doaj   +1 more source

Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. [PDF]

PLoS ONE, 2011
BACKGROUND: Treatment with tenofovir is sometimes associated with renal dysfunction. Limited information is available on this side effect in patients with small body weight, although the use of tenofovir will spread rapidly in Asia and Africa, where ...
Takeshi Nishijima, Hirokazu Komatsu, Hiroyuki Gatanaga, Takahiro Aoki, Koji Watanabe, Ei Kinai, Haruhito Honda, Junko Tanuma, Hirohisa Yazaki, Kunihisa Tsukada, Miwako Honda, Katsuji Teruya, Yoshimi Kikuchi, Shinichi Oka   +13 more
doaj   +1 more source

Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis

Antiviral Therapy, 2022
Tenofovir-based pre-exposure prophylaxis (PrEP) revolutionized the global HIV prevention landscape. Prior to the proof-of concept trial in 2010, which demonstrated that tenofovir (TFV) could prevent sexual transmission of HIV, prevention options were ...
Salim S Abdool Karim, Cheryl Baxter, Quarraisha Abdool Karim   +2 more
doaj   +1 more source

Differential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virus. [PDF]

PLoS ONE, 2014
Resistance of the reverse transcriptase (RT) of hepatitis B virus (HBV) to the tenofovir nucleotide drug has not been observed since its introduction for treatment of hepatitis B virus (HBV) infection in 2008. In contrast, frequent viral breakthrough and
Formijn J van Hemert, Ben Berkhout, Hans L Zaaijer   +2 more
doaj   +1 more source

Virological and serological outcomes in people with HIV-HBV coinfection who had discontinued tenofovir-containing antiretroviral therapy: Results from a prospective cohort study

Journal of Virus Eradication
Background and Aims: Given advances in antiretroviral therapy (ART), some people with HIV are transitioned to non-tenofovir-containing ART; the implications for people with HIV-hepatitis B virus (HBV) are unknown. We characterized HBV-related outcomes in
Amir M. Mohareb, Patrick Miailhes, Julie Bottero, Caroline Lascoux-Combe, Julie Chas, Sarah Maylin, Audrey Gabassi, Hayette Rougier, Emily P. Hyle, Constance Delaugerre, Karine Lacombe, Anders Boyd   +11 more
doaj   +1 more source

The antiviral drug tenofovir, an inhibitor of Pannexin-1-mediated ATP release, prevents liver and skin fibrosis by downregulating adenosine levels in the liver and skin. [PDF]

PLoS ONE, 2017
Fibrosing diseases are a leading cause of morbidity and mortality worldwide and, therefore, there is a need for safe and effective antifibrotic therapies.
Jessica L Feig, Aranzazu Mediero, Carmen Corciulo, Hailing Liu, Jin Zhang, Miguel Perez-Aso, Laura Picard, Tuere Wilder, Bruce Cronstein   +8 more
doaj   +1 more source

Incidence and association of renal dysfunction with a long term Tenofovir-based therapy among HIV-positive naïve cohort at Ronald Ross Hospital

PAMJ Clinical Medicine, 2020
Introduction: Tenofovir-based antiretroviral therapy places HIV-infected patients at high risk of renal dysfunction. Therefore, we evaluated if the incidence of renal dysfunction in adults HIV positive patients with long term tenofovir-based regimen use ...
Enock Wantakisha, Derick Munkonbwe, Tshula Tumba, Charles Michelo   +3 more
doaj   +1 more source